Eli Lilly CEO David Ricks

Eli Lil­ly picks up gene ther­a­py play­er Pre­vail in deal worth $1B+, mak­ing good on bolt-on pledge from ear­li­er this year

Back in Jan­u­ary, In­di­ana’s Eli Lil­ly tout­ed its plan to tack on a suite of most­ly ear­ly-stage as­sets in tar­get­ed ther­a­peu­tic ar­eas a la its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.